Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 239 | 22 | 216 |
| Samples | 83 | 12 | 70 |
| Peptides | 59 | 6 | 52 |
Function
GMNN · Geminin DNA replication inhibitor
This gene encodes a protein that plays a critical role in cell cycle regulation. The encoded protein inhibits DNA replication by binding to DNA replication factor Cdt1, preventing the incorporation of minichromosome maintenance proteins into the pre-replication complex. The encoded protein is expressed during the S and G2 phases of the cell cycle and is degraded by the anaphase-promoting complex during the metaphase-anaphase transition. Increased expression of this gene may play a role in several malignancies including colon, rectal and breast cancer. Alternatively spliced transcript variants have been observed for this gene, and two pseudogenes of this gene are located on the short arm of chromosome 16. [provided by RefSeq, Oct 2011].
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 59 amino-acid changes on canonical ENST00000230056 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in GMNN · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in GMNN – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 3/40 8% | 0/0 0% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 3/133 2% |
| Cervical Carcinoma | 1/35 3% | 5/422 1% |
| Endometrial Carcinoma | 0/42 0% | 6/612 1% |
| Non-Small Cell Lung Carcinoma | 3/304 1% | 3/1390 0% |
| Colorectal Carcinoma | 3/143 2% | 7/3239 0% |
| Breast Carcinoma | 0/144 0% | 9/3264 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 2/752 0% |
| Head and Neck Carcinoma | 1/85 1% | 3/1574 0% |
| Melanoma | 0/210 0% | 5/1899 0% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 2/810 0% |
| Bladder Carcinoma | 0/58 0% | 2/956 0% |
| Hepatocellular Carcinoma | 0/46 0% | 4/2210 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 3/1592 0% |
| Ovarian Carcinoma | 0/109 0% | 2/998 0% |
| Glioma | 0/52 0% | 4/2127 0% |
| Gastric Carcinoma | 0/74 0% | 3/1809 0% |
| Neuroendocrine Tumour | 0/154 0% | 1/577 0% |
| Biliary Tract Carcinoma | 1/54 2% | 0/950 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 2/2550 0% |
| Neuroblastoma | 0/87 0% | 1/1331 0% |
| Pancreatic Carcinoma | 0/89 0% | 1/1611 0% |
| Other Solid Cancers | 0/94 0% | 1/1515 0% |
| Prostate Carcinoma | 0/13 0% | 1/2105 0% |
| Other Blood Cancers | 0/61 0% | 1/2725 0% |
Mutation Distribution
Where GMNN is mutated · all tissues, split by cell line vs tissue
How many mutations in GMNN were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 239 mutations in GMNN
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|